Benutzer: Gast  Login
Titel:

Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Dokumenttyp:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
Autor(en):
Luber, B; Deplazes, J; Keller, G; Walch, A; Rauser, S; Eichmann, M; Langer, R; Höfler, H; Hegewisch-Becker, S; Folprecht, G; Wöll, E; Decker, T; Endlicher, E; Lorenzen, S; Fend, F; Peschel, C; Lordick, F
Abstract:
The activity of the epidermal growth factor receptor (EGFR)-directed monoclonal antibody cetuximab combined with oxaliplatin/leucovorin/5-fluorouracil (FUFOX) was assessed in first-line metastatic gastric and oesophago-gastric junction (OGJ) cancer in a prospective phase II study showing a promising objective tumour response rate of 65% and a low mutation frequency of KRAS (3%). The aim of the correlative tumour tissue studies was to investigate the relationship between EGFR gene copy numbers, a...     »
Zeitschriftentitel:
BMC Cancer
Jahr:
2011
Band / Volume:
11
Seitenangaben Beitrag:
509
Sprache:
eng
Volltext / DOI:
doi:10.1186/1471-2407-11-509
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/22152101
TUM Einrichtung:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie); Institut für Allgemeine Pathologie und Pathologische Anatomie
 BibTeX